Eurofarma is the second most innovative pharmaceutical company in Brazil according to Valor Innovation Ranking 2020
Published in: September 18, 2020
and updated in: November 4, 2021
Listen to the text
Stop the audio
São Paulo, September 2020 – Eurofarma ranks second among the most innovative pharmaceutical companies in Brazil in 2020. The outcome of the survey conducted by Valor Econômico newspaper, in partnership with consulting firm Strategy& PwC, was revealed on Thursday evening (9/17), in a virtual event that announced the winners across 23 sectors. The “Pharmaceuticals and Life Sciences” category portrays the investments of companies, best practices, and strategic solutions in the health segment, and how these companies excel in the research and development of new medications.
The 6th edition of the Valor Innovation Brazil 2020 Award had a record number of participants and listed the 150 most innovative companies in different economic activities. This year, the event also honored the Most Innovative Executive in Brazil.
Always among the five most prominent pharmaceutical labs, Eurofarma climbed one position compared to 2019. The company’s vice-president of Innovation, Martha Penna, spoke in an interview about the growing and constant investment in Research and Development (R&D), formalizing strategic partnerships with universities and startups, creating an investment fund that will help create new business for the health area, among other issues that permeate the relationship and knowledge of Eurofarma’s innovative ecosystem. The executive also mentioned the construction of the most modern research center in Latin America, which Eurofarma opened this year and will house projects related to radical innovation, biotechnology, biosimilars, and new technology platforms.
Eurofarma ranks 42nd overall.
About Eurofarma Group
As the first multinational pharmaceutical company with 100% Brazilian capital, the Eurofarma Group has been operating in the health industry since its establishment in 1972, producing and marketing innovative products and services to improve people’s quality of life. Focused on generating shared value, it operates in the areas of Prescription, Non-Prescription, and Generic Drugs, Hospital, Oncology and Veterinary. In Brazil alone, it offers 313 products, 649 dosage forms, serves 25 medical specialties and covers 89 therapeutic classes, which represent 81% of prescriptions in the brand market.
The Eurofarma Group has own operations in 20 countries, with an industrial park in Brazil and plants in 6 more Latin American countries. Reported sales totaled BRL 5.6 billion in 2019 and the Group employs over 7,000 employees.
EUROFARMA ON SOCIAL MEDIA
www.eurofarma.com.br
Facebook: @eurofarma | LinkedIn: @eurofarma
Instagram: @eurofarmalab | Twitter: @eurofarmaLab
The 6th edition of the Valor Innovation Brazil 2020 Award had a record number of participants and listed the 150 most innovative companies in different economic activities. This year, the event also honored the Most Innovative Executive in Brazil.
Always among the five most prominent pharmaceutical labs, Eurofarma climbed one position compared to 2019. The company’s vice-president of Innovation, Martha Penna, spoke in an interview about the growing and constant investment in Research and Development (R&D), formalizing strategic partnerships with universities and startups, creating an investment fund that will help create new business for the health area, among other issues that permeate the relationship and knowledge of Eurofarma’s innovative ecosystem. The executive also mentioned the construction of the most modern research center in Latin America, which Eurofarma opened this year and will house projects related to radical innovation, biotechnology, biosimilars, and new technology platforms.
Eurofarma ranks 42nd overall.
About Eurofarma Group
As the first multinational pharmaceutical company with 100% Brazilian capital, the Eurofarma Group has been operating in the health industry since its establishment in 1972, producing and marketing innovative products and services to improve people’s quality of life. Focused on generating shared value, it operates in the areas of Prescription, Non-Prescription, and Generic Drugs, Hospital, Oncology and Veterinary. In Brazil alone, it offers 313 products, 649 dosage forms, serves 25 medical specialties and covers 89 therapeutic classes, which represent 81% of prescriptions in the brand market.
The Eurofarma Group has own operations in 20 countries, with an industrial park in Brazil and plants in 6 more Latin American countries. Reported sales totaled BRL 5.6 billion in 2019 and the Group employs over 7,000 employees.
EUROFARMA ON SOCIAL MEDIA
www.eurofarma.com.br
Facebook: @eurofarma | LinkedIn: @eurofarma
Instagram: @eurofarmalab | Twitter: @eurofarmaLab